S 033188

Drug Profile

S 033188

Alternative Names: [14C]-S-033188; RG 6152; S-033188

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Shionogi
  • Developer Roche; Shionogi
  • Class Antivirals; Small molecules
  • Mechanism of Action Exonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Influenza virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 14 Nov 2016 Shionogi plans a phase III trial for Influenza in USA (NCT02954354)
  • 02 Nov 2016 Phase-III clinical trials in Influenza virus infections (In infants, In children) in Japan (PO) (JapicCTI163417)
  • 26 Oct 2016 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the IDWeek 2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top